Screener
Vaxcyte, Inc. PCVX Operating Lease Liabilities (Current)
Operating Lease Liabilities (Current) at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Line item | March 31,2026 | December 31, 2025 |
|---|---|---|
| Accrued compensation | 7,986 | 23,000 |
| Accrued contract manufacturing expenses | 134,704 | 74,654 |
| Accrued expenses | 30,247 | 31,068 |
| Operating lease liabilities — current | 6,085 | 6,124 |
| Total current liabilities | 242,082 | 205,750 |
| Operating lease liabilities — long-term | 110,212 | 111,457 |
| Total liabilities | 352,294 | 317,207 |
| Commitments and contingencies (Note 6) |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s operating lease liabilities (current)?
- Vaxcyte, Inc. (PCVX) reported operating lease liabilities (current) of $6.09M in Q1 2026.
- How has Vaxcyte, Inc.'s operating lease liabilities (current) changed year-over-year?
- Vaxcyte, Inc.'s operating lease liabilities (current) decreased by 0.7% year-over-year, from $6.13M to $6.09M.
- What is the long-term trend for Vaxcyte, Inc.'s operating lease liabilities (current)?
- Over 5 years (2020 to 2025), Vaxcyte, Inc.'s operating lease liabilities (current) has grown at a 46.7% compound annual growth rate (CAGR), from $900K to $6.12M.
- What does operating lease liabilities (current) mean?
- The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.
Ask your AI about Vaxcyte, Inc.'s operating lease liabilities (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude